Literature DB >> 14741061

Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone.

Lucyna Antkiewicz-Michaluk1, Jadwiga Wardas, Jerzy Michaluk, Irena Romaska, Andrzej Bojarski, Jerzy Vetulani.   

Abstract

The aim of this paper was to investigate whether rotenone, a pesticide causing experimental parkinsonism, causes direct damage to dopaminergic structure when injected intracerebrally and whether this action may be prevented by peripheral administration of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), an endogenous compound with anti-dopaminergic activity. Male Wistar rats were injected unilaterally into the median forebrain bundle with 2 microg rotenone, and received 1MeTIQ, 50 mg/kg i.p. 1 h before and then daily for 21 d. To compare the effect of intracerebral and peripheral treatment, rotenone was also given once or for 7 d in a dose of 10 mg/kg s.c. Dopamine, serotonin and their metabolites were assessed by HPLC in the substantia nigra and striatum. While a single subcutaneous rotenone dose did not produce any change in striatal dopamine metabolism, the multiple treatments resulted in changes suggesting a shift in the metabolism towards oxidative desamination and reduction of O-methylation. In contrast to systemic injections, intracerebral-administered rotenone produced a decrease in dopamine and its metabolites content in the striatum (dopamine decrease by 70%) and substantia nigra (dopamine decrease by 35%), without affecting the serotonin system. As those changes were observed 21 d after the injection of rotenone, they suggest a durable neurotoxic effect. The treatment with 1MeTIQ strongly reduced the fall of striatal dopamine concentration. The data suggest that rotenone given peripherally affects metabolic processes in dopaminergic neurons, and this seems to result from its neurotoxic action, which may be observed after an intracerebral injection. 1MeTIQ is able to counteract the damaging action of rotenone and seems to be a potential neuroprotective agent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741061     DOI: 10.1017/S1461145703004036

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  17 in total

1.  Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.

Authors:  Camila G Moreira; Janaína K Barbiero; Deborah Ariza; Patrícia A Dombrowski; Pamela Sabioni; Mariza Bortolanza; Claudio Da Cunha; Maria A B F Vital; Marcelo M S Lima
Journal:  Neurotox Res       Date:  2011-09-28       Impact factor: 3.911

2.  An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats.

Authors:  L Antkiewicz-Michaluk; M Filip; J Michaluk; I Romańska; E Przegaliński; J Vetulani
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 3.  Not Just from Ethanol. Tetrahydroisoquinolinic (TIQ) Derivatives: from Neurotoxicity to Neuroprotection.

Authors:  Alessandra T Peana; Valentina Bassareo; Elio Acquas
Journal:  Neurotox Res       Date:  2019-05-02       Impact factor: 3.911

Review 4.  A guide to neurotoxic animal models of Parkinson's disease.

Authors:  Kim Tieu
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 5.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

6.  1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonism-inducing toxin, strongly potentiates MAO-dependent dopamine oxidation and impairs dopamine release: ex vivo and in vivo neurochemical studies.

Authors:  Agnieszka Wasik; Irena Romańska; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2009-02-10       Impact factor: 3.911

7.  1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat.

Authors:  Małgorzata Pietraszek; Jerzy Michaluk; Irena Romańska; Agnieszka Wasik; Krystyna Gołembiowska; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2009-08-01       Impact factor: 3.911

8.  Both stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release.

Authors:  Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik; Irena Romańska; Andrzej Bojarski; Jerzy Michaluk
Journal:  Neurotox Res       Date:  2010-11-11       Impact factor: 3.911

9.  Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.

Authors:  Paulien Gm Ravenstijn; Henk-Jan Drenth; Michael J O'Neill; Meindert Danhof; Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2012-02-08

10.  Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons.

Authors:  Hsiao-Yun Lin; Wei-Lan Yeh; Bor-Ren Huang; Chingju Lin; Chih-Ho Lai; Ho Lin; Dah-Yuu Lu
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.